{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:36Z","timestamp":1792796796052,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer\u2019s disease (AD). Anti-amyloid monoclonal antibodies can substantially reverse amyloid plaque pathology and may modify the course of the disease by slowing or stopping its clinical progression. Several molecules targeting amyloid have failed in clinical development due to drug-related factors (e.g., treatment-limiting adverse events, low potency, poor brain penetration), study design\/methodological issues (e.g., disease stage, lack of AD pathology confirmation), and other factors. The US Food and Drug Administration\u2019s approval of aducanumab, an anti-amyloid monoclonal antibody as the first potential disease-modifying therapy for AD, signaled the value of more than 20 years of drug development, adding to the available therapies the first nominal success since cholinesterase inhibitors and memantine were approved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Body<\/jats:title>\n                    <jats:p>Here, we review over 2 decades of gantenerumab development in the context of scientific discoveries in the broader AD field. Key learnings from the field were incorporated into the gantenerumab phase 3 program, including confirmed amyloid positivity as an entry criterion, an enriched clinical trial population to ensure measurable clinical decline, data-driven exposure-response models to inform a safe and efficacious dosing regimen, and the use of several blood-based biomarkers. Subcutaneous formulation for more pragmatic implementation was prioritized as a key feature from the beginning of the gantenerumab development program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-01110-8","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T09:05:06Z","timestamp":1669712706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Randall J.","family":"Bateman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Schobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Seleri","family":"Assun\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle S.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"1","key":"1110_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius H, Neundorfer G. The discovery of Alzheimer\u2019s disease. Dialogues Clin Neurosci. 2003;5(1):101\u20138.","journal-title":"Dialogues Clin Neurosci"},{"issue":"12","key":"1110_CR2","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82(12):4245\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6311","key":"1110_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u20136.","journal-title":"Nature."},{"issue":"10","key":"1110_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12(10):383\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"1110_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"1110_CR6","volume-title":"FDA grants accelerated approval for Alzheimer\u2019s drug","author":"US Food & Drug Administration","year":"2021","unstructured":"US Food & Drug Administration. FDA grants accelerated approval for Alzheimer\u2019s drug. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug. Accessed 17 June 2022."},{"key":"1110_CR7","unstructured":"Lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer\u2019s disease. News release. Biogen. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary. September 27, 2022. Accessed 27 Sep 2022."},{"key":"1110_CR8","volume-title":"The clinical development history of gantenerumab, a subcutaneous anti-A\u03b2 monoclonal antibody for early Alzheimer\u2019s disease: building on lessons from the past and paving a path for the future","author":"RJ Bateman","year":"2022","unstructured":"Bateman RJ, Smith J, Fox NC, Black SE, Shij Turner RS, et al. The clinical development history of gantenerumab, a subcutaneous anti-A\u03b2 monoclonal antibody for early Alzheimer\u2019s disease: building on lessons from the past and paving a path for the future. San Diego: Presented at: Alzheimer\u2019s Association International Conference Annual Meeting; 2022."},{"issue":"1","key":"1110_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"1110_CR10","first-page":"1359","volume":"7","author":"D Novakovic","year":"2013","unstructured":"Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer\u2019s disease. Drug Des Devel Ther. 2013;7:1359\u201364.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1110_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198\u2013207.","journal-title":"Arch Neurol"},{"issue":"16 Supplement","key":"1110_CR12","doi-asserted-by":"crossref","first-page":"P6.087","DOI":"10.1212\/WNL.88.16_supplement.P6.087","volume":"88","author":"B Bohrmann","year":"2017","unstructured":"Bohrmann B, Oroszlan-Szovik K, Anquez V, Baumann K, Kusznir E, Gerber F, et al. A comparative study of binding properties of gantenerumab and aducanumab analog to aggregated amyloid-beta. Neurology. 2017;88(16 Supplement):P6.087.","journal-title":"Neurology"},{"issue":"1","key":"1110_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):95.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"1110_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med. 2021;27(7):1187\u201396.","journal-title":"Nat Med"},{"issue":"2","key":"1110_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","volume":"24","author":"RS Black","year":"2010","unstructured":"Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24(2):198\u2013203.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"1110_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1110_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"1110_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13\u201321.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1110_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241\u20139.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1110_CR20","first-page":"106","volume":"87","author":"HM Arrighi","year":"2016","unstructured":"Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melan\u00e7on D, et al. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry. 2016;87(1):106\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7806","key":"1110_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71\u20136.","journal-title":"Nature."},{"key":"1110_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fneur.2015.00207","volume":"6","author":"JC DiFrancesco","year":"2015","unstructured":"DiFrancesco JC, Longoni M, Piazza F. Anti-Abeta autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer\u2019s disease and cerebral amyloid angiopathy. Front Neurol. 2015;6:207.","journal-title":"Front Neurol"},{"issue":"12","key":"1110_CR23","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1161\/STROKEAHA.117.018974","volume":"48","author":"M Pichler","year":"2017","unstructured":"Pichler M, Vemuri P, Rabinstein AA, Aakre J, Flemming KD, Brown RD Jr, et al. Prevalence and natural history of superficial siderosis: a population-based study. Stroke. 2017;48(12):3210\u20134.","journal-title":"Stroke."},{"issue":"4","key":"1110_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321.","journal-title":"N Engl J Med"},{"key":"1110_CR25","unstructured":"ClinicalTrials.gov: A study of gantenerumab in participants with prodromal Alzheimer\u2019s disease (SCarlet RoAD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01224106 (2021). Accessed 15 June 2022."},{"key":"1110_CR26","unstructured":"ClinicalTrials.gov: A study of a high concentration liquid formulation versus a lyophilized formulation of gantenerumab in healthy volunteers. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01636531 (2016). Accessed 15 June 2022."},{"key":"1110_CR27","unstructured":"ClinicalTrials.gov: A study investigating the bioavailability of a high concentration liquid formulation versus a reference lyophilized formulation of gantenerumab in healthy volunteers. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02133937 (2016). Accessed 15 June 2022."},{"key":"1110_CR28","unstructured":"ClinicalTrials.gov: A study to assess the impact of speed and site of subcutaneous injection on pain, tolerability, safety, and pharmacokinetics of gantenerumab in healthy participants. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02882009 (2019). Accessed 15 June 2022."},{"issue":"1","key":"1110_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clinthera.2019.11.015","volume":"42","author":"A Portron","year":"2020","unstructured":"Portron A, Jordan P, Draper K, Muenzer C, Dickerson D, van Iersel T, et al. A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers. Clin Ther. 2020;42(1):108-20.e1.","journal-title":"Clin Ther"},{"issue":"7","key":"1110_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology."},{"issue":"15 Supplement","key":"1110_CR31","doi-asserted-by":"crossref","first-page":"P6.179","DOI":"10.1212\/WNL.90.15_supplement.P6.179","volume":"90","author":"C Hofmann","year":"2018","unstructured":"Hofmann C, Gieschke R, Retout S, Milosavljevic-Ristic S, Voyle N, Delmar P, et al. Optimizing the gantenerumab phase 3 dosing regimen through PK\/PD modeling and clinical trial simulations. Neurology. 2018;90(15 Supplement):P6.179.","journal-title":"Neurology."},{"key":"1110_CR32","unstructured":"ClinicalTrials.gov: A study of gantenerumab in participants with mild Alzheimer disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02051608 (2021). Accessed 15 June 2022."},{"issue":"7S_Part_4","key":"1110_CR33","doi-asserted-by":"publisher","first-page":"P240","DOI":"10.1016\/j.jalz.2018.06.2379","volume":"14","author":"N Voyle","year":"2018","unstructured":"Voyle N, Abi-Saab D, Klein G, Hofmann C, Delmar P, Pross N, et al. O1-09-02: the effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (CSF) in the Marguerite RoAD study. Alzheimers Dement. 2018;14(7S_Part_4):P240.","journal-title":"Alzheimers Dement"},{"key":"1110_CR34","unstructured":"ClinicalTrials.gov: Efficacy and safety study of gantenerumab in participants with early Alzheimer\u2019s disease (AD). 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03444870. Accessed 15 June 2022."},{"key":"1110_CR35","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1038\/psp.2013.54","volume":"2","author":"I Delor","year":"2013","unstructured":"Delor I, Charoin JE, Gieschke R, Retout S, Jacqmin P. Modeling Alzheimer\u2019s disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI. CPT Pharmacometrics Syst Pharmacol. 2013;2:e78.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7618","key":"1110_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PB, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature."},{"issue":"4","key":"1110_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/cpt.2535","volume":"111","author":"S Retout","year":"2022","unstructured":"Retout S, Gieschke R, Serafin D, Weber C, Frey N, Hofmann C. Disease modeling and model-based meta-analyses to define a new direction for a phase III program of gantenerumab in Alzheimer\u2019s disease. Clin Pharmacol Ther. 2022;111(4):857\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1110_CR38","first-page":"3","volume":"8","author":"G Klein","year":"2021","unstructured":"Klein G, Delmar P, Kerchner GA, Hofmann C, Abi-Saab D, Davis A, et al. Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J Prev Alzheimers Dis. 2021;8(1):3\u20136.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1110_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11(1):101.","journal-title":"Alzheimers Res Ther"},{"key":"1110_CR40","doi-asserted-by":"crossref","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315.","DOI":"10.1016\/j.jalz.2014.07.003"},{"issue":"7S_Part_4","key":"1110_CR41","doi-asserted-by":"publisher","first-page":"P241","DOI":"10.1016\/j.jalz.2018.06.2382","volume":"14","author":"M Andjelkovic","year":"2018","unstructured":"Andjelkovic M, Abi-Saab D, Delmar P, Pross N, Voyle N, Klein G, et al. O1-09-05: update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the SCarlet RoADy study in patients with prodromal Alzheimer\u2019s disease after approximately 2 years of study duration. Alzheimers Dement. 2018;14(7S_Part_4):P241\u20132.","journal-title":"Alzheimers Dement"},{"issue":"7S_Part_4","key":"1110_CR42","doi-asserted-by":"publisher","first-page":"P241","DOI":"10.1016\/j.jalz.2018.06.2381","volume":"14","author":"D Abi-Saab","year":"2018","unstructured":"Abi-Saab D, Andjelkovic M, Pross N, Delmar P, Voyle N, Klein G, et al. O1-09-04: update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite RoAD study in patients with mild Alzheimer\u2019s disease (AD) after approximately two years of study duration. Alzheimers Dement. 2018;14(7S_Part_4):P241.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1110_CR43","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"issue":"1","key":"1110_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8\u201319.","journal-title":"Alzheimers Dement"},{"key":"1110_CR45","unstructured":"ClinicalTrials.gov: Dominantly Inherited Alzheimer Network Trial: an opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer\u2019s disease caused by a genetic mutation. Master protocol DIAN-TU001 (DIAN-TU). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01760005 (2021). Accessed 15 June 2022."},{"key":"1110_CR46","unstructured":"ClinicalTrials.gov: Safety and efficacy study of gantenerumab in participants with early Alzheimer\u2019s disease (AD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443973 (2022). Accessed 15 June 2022."},{"key":"1110_CR47","first-page":"S1","volume":"8","author":"C Lane","year":"2021","unstructured":"Lane C, Bullain S, Thanasopoulou A, Delmar P, Searle A, Boada M, et al. ROC12- baseline characteristics of the GRADUATE studies: phase III randomized, placebo-controlled studies investigating subcutaneous gantenerumab in participants with early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2021;8:S1-72.","journal-title":"J Prev Alzheimers Dis"},{"key":"1110_CR48","first-page":"S19","volume":"6","author":"K Sink","year":"2019","unstructured":"Sink K, Djakovic S, Smith JW, Smith J, Hu N, Mackey H, et al. FCSRT inclusion criteria support recruitment of a population with early Alzheimer\u2019s disease likely to progress over 24 months: results from the CREAD trial. J Prev Alzheimers Dis. 2019;6:S19\u201320.","journal-title":"J Prev Alzheimers Dis"},{"issue":"15 Supplement","key":"1110_CR49","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1212\/WNL.96.15_supplement.2234","volume":"96","author":"A Searle","year":"2021","unstructured":"Searle A, Thanasopoulou A, Kenton J, Gabriel M, Voyle N, Baudler M, et al. Utilization of home nursing to mitigate the impact of COVID-19 on the conduct of the gantenerumab graduate trials. Neurology. 2021;96(15 Supplement):2234.","journal-title":"Neurology."},{"issue":"18 Supplement","key":"1110_CR50","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1212\/WNL.98.18_supplement.1634","volume":"98","author":"C Lane","year":"2022","unstructured":"Lane C, Thanasopoulou A, Delmar P, Searle A, Mazzo F, Ehrhard P, et al. Postgraduate open-label rollover study: evaluation of subcutaneous gantenerumab long-term safety, tolerability, and efficacy in participants with Alzheimer\u2019s disease. Neurology. 2022;98(18 Supplement):1634.","journal-title":"Neurology."},{"key":"1110_CR51","volume-title":"GRADUATION study design: evaluation of once-weekly subcutaneous administration of gantenerumab on brain amyloid load","author":"F Boess","year":"2021","unstructured":"Boess F, Sakaoka S, Abi-Saab D, Scelsi M, Delmar P, Hoffman C, et al. GRADUATION study design: evaluation of once-weekly subcutaneous administration of gantenerumab on brain amyloid load. Denver: Poster presented at Alzheimer\u2019s Association International Conference (AAIC); 2021."},{"issue":"5","key":"1110_CR52","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neurol.2022.03.001","volume":"178","author":"J Baker","year":"2022","unstructured":"Baker J, Schott JM. AD and its comorbidities: an obstacle to develop a clinically efficient treatment? Rev Neurol (Paris). 2022;178(5):450\u20139.","journal-title":"Rev Neurol (Paris)"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01110-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01110-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01110-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:51:15Z","timestamp":1728481875000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01110-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1110"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01110-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies reviewed in this article were conducted globally across multiple sites. Each study was approved by individual institutional ethics committees or institutional review boards and conducted in accordance with the principles of the Declaration of Helsinki and good clinical practice. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RJB is a co-founder and on the scientific advisory board of C2N Diagnostics and reports research support from Abbvie; Avid Radiopharmaceuticals; Biogen; Centene; Eisai; Eli Lilly and Company; Genentech, Inc.; F. Hoffmann-La Roche; Janssen; and United Neuroscience. JC has provided consultation to Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Merck, Novo Nordisk, Ono, Otsuka, ReMYND, Resverlogix, Roche, Signant Health, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory. S. Schobel was an employee and shareholder of F. Hoffmann-La Roche Ltd. at the time this work was completed. S. Salloway was the co-chair of the Investigator Steering Committee for the aducanumab phase 3 program, served as a site PI for the aducanumab and lecanemab phase 3 studies and the donanemab phase 2 trial, and was the project arm leader for gantenerumab in DIAN-TU. He has received consulting income from Biogen, Lilly, Roche, Genentech, Bolden, Amylyx, Prothena, and Eisai. He has no stock or royalties related to any medication in development. He serves on the planning committee for the National Disease Modifying Treatment and Diagnostic Registry Work Group and is a member of the ADRD Therapeutics Work Group. BV has provided consultation to Biogen, Eisai, Grifols, Novo Nordisk, Roche, and Lilly. MB receives fees from Lab. Servier and Lilly for consulting, as well as from Lilly, Nutricia, Roche, and Schwabe for lectures. She receives fees from Lilly, Biogen, Roche, and Schwabe for advisory boards. SEB reports receiving in-kind research support from Avid Radiopharmaceuticals and GE Healthcare, assisting in developing the ADVANCE Program, a Canadian physician webinar series on dementia sponsored by Biogen and has presented on neuroimaging. Dr. Black has also been an ad hoc consultant to Biogen, F.\u00a0Hoffman La Roche, and Roche Canada. Dr. Black acknowledges grant support from the Canadian Institutes of Health Research, the NIH, Leducq Foundation, Dasman Institute, Alzheimer Drug Discovery Foundation, the Weston Foundation, the Ontario Brain Institute, Brain Canada, and the Heart and Stroke Foundation of Canada. KB has served as a consultant and at scientific advisory boards and\/or data monitoring committees for Abcam, Axon, Biogen, JOMDD\/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. PF and GK are employees of F. Hoffman-La Roche and own stock or stock options in F. Hoffmann-La Roche Ltd. SSA is an employee of Genentech, Inc., part of F. Hoffmann-La Roche. JS is an employee of Roche Products Ltd. and owns stock options in F. Hoffmann-La Roche Ltd. RD is an employee of Genentech, Inc., part of F. Hoffmann-La Roche Ltd., and owns stock in F. Hoffmann-La Roche Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}